What if there was a way to tackle the flu more effectively? Every year, millions suffer from the flu, leading to missed work, school, and even hospital visits. Traditional flu vaccines have been around for a while, but they don't always provide the best protection. This new study is exploring mRNA vaccines, which have shown promise in other areas, like COVID-19. Participants in this study will receive one dose of either an experimental mRNA flu vaccine or a standard flu vaccine. Over six months, researchers will monitor how well these vaccines trigger the immune system to fight off the flu virus. The hope is that this could lead to a more effective way to prevent the flu and its complications. However, it's important to note that this is still in the early phases, and we need to see how safe and effective these new vaccines really are. If they work, we could be looking at a future where flu seasons are less severe, which is something everyone can look forward to.
Phase 2 Trial Evaluates mRNA Influenza Vaccines' Safety and Immunogenicity in AdultsCould This New Vaccine Help Us Finally Beat the Flu?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Monitor outcomes of mRNA flu vaccines for safety and immune response in ongoing Phase 2 trial.
This Phase 2 study, sponsored by Pfizer, aims to evaluate the safety and immunogenicity of five mRNA-based influenza vaccines in a cohort of 770 healthy adults aged 18 and older. Participants will receive a single dose of either one of the experimental vaccines or an approved comparator vaccine, with follow-up over approximately 6 months. The primary endpoints focus on the percentage of participants experiencing prespecified local and systemic reactions, as well as adverse events following vaccination. Participants will attend at least three study visits, during which blood samples and nasal swabs will be collected to assess immune response. As the study is currently recruiting, specific statistical outcomes, such as hazard ratios, odds ratios, or p-values, are not yet available. The trial's findings will provide critical insights into the safety profile and immune response elicited by these mRNA vaccines, potentially informing future influenza vaccination strategies.
What this means for you:
A new mRNA flu vaccine could offer better protection, making flu seasons healthier for everyone. More on Influenza
High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 months
High-dose flu shots show greater protection for young children in China
This randomized, double-blind study in 3,000 Chinese children aged 6 to 35 months found an investigational high-dose quadrivalent influenza …
A new study in China shows high-dose flu vaccines work as well as or better than standard shots for toddlers, offering stronger protection a…
mRNA-1010 shows superior efficacy against influenza in older adults
New flu shot cuts illness by 27 percent in adults over 50
A phase 3 trial found mRNA-1010 vaccine had 26.6% relative efficacy versus standard comparator in adults 50+.
A new mRNA flu vaccine reduced confirmed flu illness by 27 percent compared with the standard shot in adults 50 and older.
Systematic review and meta-analysis finds bacterial co-infection in 17.3% of hospitalized influenza patients
Hospital data shows high rates of bacterial co-infection in influenza patients
This systematic review and meta-analysis of 111,889 hospital-attended patients with laboratory-confirmed influenza found a pooled prevalence…
Analysis of over 111,000 patients reveals that bacterial co-infection occurs in 17.3% of hospital cases with confirmed influenza infection.
Six H5N1 vaccine formulations showed immunogenicity and acceptable safety in 420 healthy children aged 6 months to 9 years
Higher adjuvant content boosts immunity in children without added safety risks
This phase 2, observer-blind, multicenter study evaluated six formulations of MF59-adjuvanted H5N1 vaccine in 420 healthy infants and childr…
A Phase 2 trial in healthy children found that higher adjuvant content improved immune responses to an H5N1 vaccine without increasing side …
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Healthy Adults
Intervention(s): Vaccine Candidate #1 (BIOLOGICAL), Vaccine Candidate #2 (BIOLOGICAL), Vaccine Candidate #3 (BIOLOGICAL), Vaccine Candidate #4 (BIOLOGICAL), Vaccine Candidate #5 (BIOLOGICAL)
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus).
This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison.
Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.
Primary Outcome(s): Percentage of participants reporting prespecified local reactions following vaccination; Percentage of participants reporting prespecified systemic events following vaccination.; Percentage of participants reporting adverse events (AEs) following vaccination.
Enrollment: 770 (ESTIMATED)
Lead Sponsor: Pfizer
Start: 2026-02-23 | Primary Completion: 2027-06-22
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
FDA Approves Linezolid Injection for Gram-Positive Infections Including Pneumonia and Skin Infections
FDA approves new antibiotic injection for serious bacterial infections
The FDA approved linezolid injection for nosocomial pneumonia, community-acquired pneumonia, complicated skin infections, and vancomycin-res…
The FDA approved linezolid injection for treating serious infections like pneumonia and skin infections caused by certain bacteria, includin…
Intrawound vancomycin powder reduces postoperative infection risk (OR 0.59) in high-risk fracture fixation cases
Vancomycin Powder May Reduce Infections After High Risk Fractures
This meta-analysis of 3185 patients found that intrawound vancomycin powder significantly reduced postoperative infection rates (OR 0.59; 95…
A review of data suggests that using vancomycin powder in wounds may lower infection rates for patients with serious bone fractures.
Risk-adapted HLA delisting and imlifidase enable deceased-donor kidney transplantation for highly sensitized candidates
New guide helps transplant kidneys for hardest-to-match patients
This expert consensus provides a practical guideline for managing highly sensitized adult patients on the waitlist for deceased-donor kidney…
A new expert guide shows how to safely transplant kidneys into highly sensitized patients who have few options left.
Regenerative endodontic procedures may lead to unusual root morphology in immature teeth
Regenerative procedures can lead to unusual tooth root growth
This case report with literature review describes 2 immature teeth with pulp necrosis secondary to dens evaginatus treated with regenerative…
A new look at dental treatments shows that while some procedures save teeth, they can sometimes cause unexpected changes in how roots grow.
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …